|
| | | | | | | | | | |
| Name | Indication | Approved | Economics | Mechanism | IP | | Price | 790 | |
| Arcalyst (rilonacept) | CAPS | 2/1/2008 | 1 | IL-1 | Antibody | | Shares | 109.325532 | Q422 |
| Zaltrap (aflibercept) | mCRC | | SNY | VEGF | | | MC | 86367.17027999999 | |
| Dupixent (dupilumab) | Asthma, AD | | SNY | IL-4 | | | Cash | 14334 | Q422 |
| Libtayo (cemiplimab) | NSCLC | | 100%? | PD-1 | | | Debt | 1980.7 | Q422 |
| Eylea (aflibercept) | AMD | | BAY | VEGF | Antibody | | EV | 74013.87027999999 | |
| Kevzara (sarilumab) | RA | | | IL-6R | Antibody | | | | |
| Evkeeza (evinacumab) | Hypercholesterolemia | | | ANGPTL3 | | | | | |
| Praluent (alirocumab) | Hypercholesterolemia | | SNY | PCSK9 | Antibody | | | | |
| | | Phase | | | | | | | |
| odronextamab | DLBCL | III | | CD20xCD3 | | | | | |
| linvoseltamab | MM | | | BCMAxCD3 | | | | | |
| NTLA-2001 | ATTR | | NTLA | CRISPR | | | | | |
| pozelimab | CHAPLE | Filed | | C5 | | | | | |
| fasinumab (REGN475) | Pain | I (on hold) | | NGF | | | | | |
| REGN7257 | Aplastic Anemia | | | IL-2Rgamma | | | | | |
| fianlimab | | | | | | | | | |
| garetosmab | FOP | | | Activin A | | | | | |
| REGN7075 | NSCLC | | | EGFR/CD28 | | | | | |
| REGN7999 | Iron Overload | | | TMPRSS6 | | | | | |
| REGN6569 | | | | GITR | | | | | |
| REGN5093 | | | | MET | | | | | |
| REGN4336 | Prostate Cancer | | | PSMAxCD3 | | | | | |
| REGN7508 | Thrombosis | | | Factor XI | | | | | |
| mibavademab | Lipodystrophy | | | LEPR agonist | | | | | |
| | | | | | | | | | |
| | | | | Jun 2010: announced positive results of PRE-SURGE 1 of Arcalyst in gout prevention | | | | | |
| | | | | Nov 2010: announced positive VIEW 1 & 2 results of VEGF-Trap in wet AMD | | | | | |
| | | | | Dec 2010: announced positive COPERNICUS study of VEGF-Trap for CRVO | | | | | |
| | | | | Feb 2011: announced positive results of PRE-SURGE 2 and RE-SURGE of Arcalyst in gout | | | | | |
| | | | | Feb 2011: BLA for VEGF-Trap submitted to FDA | | | | | |
| | | | | Apr 2011: announced positive GALILEO study of VEGF-Trap inCRVO (Bayer-led) | | | | | |
| | | | | Apr 2011: BLA for VEGF-Trap accepted and granted Priority Review | | | | | |
| | | | | Apr 2011: Bayer initiated Ph3 VIVID-DME study ex-US | | | | | |
| | | | | Apr 2011: announced positive Ph3 VELOUR study of ZALTRAP plus FOLFIRI in second-line mCRC | | | | | |
| | | | | 1H11: Bayer will submit application for VEGF-Trap in EU | | | | | |
| | | | | 1H11: plan to submit application for marketing approval of VEGF-Trap in CRVO in the US | | | | | |
| | | | | mid-'11: interim analysis of Ph3 VENICE study of ZALTRAP as first-line tx for hormone-refractory prostate cancer in combo w docetaxel/prednisone | | | | | |
| | | | | mid-'11: submit sBLA for Arcalyst in gout to FDA | | | | | |
| | | | | Aug 20, 2011: PDUFA for VEGF-Trap for wet AMD | | | | | |
| | | | | 2H11: plan to submit regulatory application for ZALTRAP in second-line mCRC to FDA & EMA | | | | | |
| | | | | 2H11: plan to initiate another DME study of VEGF-Trap in US | | | | | |
| | | | | 2H11: results fr Ph2 AFFIRM study of ZALTRAP plus FOLFOX in first-line mCRC | | | | | |
| | | | | 2012: Bayer will submit application for regulatory approval of VEGF-Trap in CRVO | | | | | |
| | | | | 2012: final results for Ph3 VENICE study of ZALTRAP in prostate cancer | | | | | |
| | | | | Nov. 11: Eylea approved. Priced at $1,700/injection. | | | | | |